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Abstract
Background: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both
adenocarcinoma and carcinoid tumor. While its malignant potential remains unclear, GCC's are more aggressive than
conventional carcinoid. The clinical presentations of this neoplasm are also varied. This review summarizes the published
literature on GCC of the appendix. The focus is on its diagnosis, histopathological aspects, clinical manifestations, and
management.
Methods: Published studies in the English language between 1966 to 2004 were identified through Medline keyword search
utilizing terms "goblet cell carcinoid," "adenocarcinoid", "mucinous carcinoid" and "crypt cell carcinoma" of the appendix.
Results: Based on the review of 57 published papers encompassing nearly 600 diagnosed patients, the mean age of presentation
for GCC of the appendix was 58.89 years with equal representation in both males and females. Accurate diagnosis of this
neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of
submucosal growth and usually lacks the formation of a well-defined tumor mass. The mesoappendix was involved in 21.64%
followed by perineural involvement in 2.06%. The most common clinical presentations in order of frequency were acute
appendicitis in 22.5%; asymptomatic in 5.4%; non-localized abdominal pain in 5.15% and an appendicular mass in 3.09%. The most
common surgical treatment of choice was appendectomy with right hemicolectomy in 34.70% followed by simple appendectomy
in 24.57%. Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most
common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%. Local lymph node involvement was seen in
8.76% of patients at the time of diagnosis. The reported 5-year survival ranges from 60 % to 84%. GCC's of the appendix remains
a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon
diagnosis and successful surgical extirpation.
Conclusion: GCC of the appendix is a rare neoplasm. Due to its wide range of presentation, this tumor should be considered
as a possible diagnosis in many varied situations leading to abdominal surgery. Histopathological features such as increased
number of Paneth cells, increased amount of mucin secretion and presence of pancreatic polypeptide may predict a more
aggressive behavior. The advocated plan of management recommended for patients with tumors that involve the adjacent
caecum or with high-grade tumors with histological features such as an increased mitotic rate involve initial appendectomy with
completion right hemicolectomy due to the high possibility of local recurrence with intraperitoneal seeding prior to lymph node
involvement and a 20% risk of metastatic behavior. In female patients with GCC of the appendix regardless of age, bilateral
salpingo-oophorectomy is advocated. In cases with obvious spread of the disease chemotherapy, mostly with 5-FU and
leucovorin is advised. Cytoreductive surgery with adjuvant intraperitoneal chemotherapy can offer improved survival in cases
with advanced peritoneal dissemination.
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Cancer of the appendix is an uncommon disease [1].
Appendiceal carcinoids however are found in 1 out of
every 300 appendectomies. Since more than 30 years ago,
a new variant type of epithelial tumor of appendix has
been recognized [2,3]. This tumor is reported under differ-
ent names including goblet cell carcinoid (GCC), adeno-
carcinoid, mucinous carcinoid, intermediate type of
carcinoid, crypt cell carcinoma, amphicrine (endo-exo-
crine) neoplasia, composite tumor and microglandular
carcinoma [2,4,5]. All names except GCC have been omit-
ted from the current World Health Organization (WHO)
classification [6]. In general, GCC (International Classifi-
cation of Disease for Oncology, ICD-O 8243/3) is a rare
neuroendocrine tumor of the vermiform appendix, com-
prising approximately 6% of appendiceal carcinoids and
usually occurs in the pure form [7-9]. Some characteristics
including its intramural position in the appendix, the con-
tinuity with the basiglandular cells of the mucus mem-
brane, and it's generally well-differentiated suggesting its
relation to carcinoid [10]. Nevertheless, some authors say
that this tumor is far more closely related to intestinal
crypts than to carcinoids and insist on not considering
this tumor as a variant of carcinoids [11]. GCC has both
endocrine and glandular differentiation [9]. This tumor
appears to combine features of epithelial and carcinoid
neoplasms and in addition the surface mucosal epithe-
lium is not neoplastic [12]. Furthermore, in comparison
to the other carcinoid tumors, GCC is usually larger in size
[12].
Subbuswamy et al described the first report of GCC in
1974 [10]. This type of neoplasm predominantly occurs
in the appendix as a distinct pathological entity [13,14]
and has uncertain distinct biological behavior [15]. The
histology and biology appears to be intermediate between
carcinoid tumors and adenocarcinomas [16]. Some
authors believe that this tumor usually presents as a low-
grade malignancy and metastases are uncommon [17].
Yet, in general, it is believed that it has a more aggressive
natural history than classic appendiceal carcinoids with
variable malignant potential; thus, it requires a different
surgical approach than is usually advocated for classic car-
cinoids [3]. The tumor most commonly infiltrates the
entire appendix transmurally [6]. Anatomically, GCC's are
usually located near the tip of the appendix [18]. Preoper-
ative diagnosis is rare and patients usually present with
acute appendicitis [2]. The GCC cells are probably APUD
(amine precursor uptake and decarboxylation) derived
cells with both mucinous and entrochromafin granules
[19]. The number of patients who were diagnosed with
this neoplasm based on the Medline search is less than
600 worldwide. The purpose of this study is to review the
literature regarding this rare neoplasm to identify diag-
nostic, clinical, histological features, treatment guidelines
and understand the prognosis that is somehow different
from the usual appendiceal carcinoid.
History of GCC of the appendix
Appendiceal tumors that share the histological character-
istics of carcinoids and adenocarcinomas have been recog-
nized since the 1960s, with early reports by Gibbs, Bates
and Butler, Rosai and Rodriguez [5]. In 1969, Gagne et al
described 3 unusual tumors of appendix with common
features of 1) association of nests of entrochromafin cells
with mucus secreting glandular structures; 2) integrity of
the appendiceal mucosa, and 3) an infiltrative pattern
similar to carcinoid tumors but with the propensity to
invade nerves [17]. In 1974, Klein reported three cases of
mucinous carcinoid tumor of appendix [20] but the first
reported cases under the name of GCC were by Sub-
buswamy et al in 1974 [10]. After that Abt et al reported
microscopical demonstration of the cells of the other
known cases with GCC of the appendix [21]. DiPaola et al
reported the first case of appendico-vesical fistula due to
appendix abscess with GCC in 1976 [22]. In 1978 Warkel
et al reported 39 cases of GCC and revealed more aspects
about this neoplasm [23]. In 1979, Warner et al described
the origin of these cells as being endodermal in origin and
explained that these cells arise from crypt base stem cells
[19]. In 1980, Ratzenhofer et al explained this neoplasm
as amphicrine (endo-exocrine) neoplasia [4]. Recent
reports are more focused on the genetic aspects and
molecular levels of the pathogenesis of this neoplasm
[16,7,24]. Due to the paucity of reported cases and non-
specific presentations e.g., acute appendicitis, diagnosis of
this neoplasm requires a high degree of astute observa-
tions in an otherwise inflamed appendix. This is primarily
attributed to its predominant submucosal growth and
lack of forming a well-defined mass within the appendix.
Epidemiologic characteristics and etiopathogenetic 
factors
GCC accounts for less than 5% of primary tumors of the
appendix [25]. Based on a review on 227 patients with
GCC of the appendix, GCC occurs equally in men and
women and with higher occurrence in the white race [1].
Aizawa et al explained that the mean age for GCC is 58.8
years, whereas that for carcinoid tumor is 35.9 years [26].
The mean age at diagnosis of GCC is between malignant
carcinoid (38 years) and mucinous adenocarcinoma (60
years) [1]. The mean age for those presenting with more
localized tumor is significantly lower, compared to the
mean age of those with spread beyond the appendix [27].
In addition, the mean age of goblet cell type is signifi-
cantly higher than the tubular carcinoid of the appendix
[28]. In contrast to appendiceal carcinoids that metasta-
size in 2 to 5% of cases, GCCs metastasize in 15 to 30% of
cases [25].Page 2 of 11
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a pluripotent cell with divergent neuroendocrine and
mucinous differentiation and with dysregulation of the
cell cycle [15]. There is a large reserve G0/G1 pool of
pluripotent cells that remain noninvasive until further
genetic instability is acquired by the cell [15]. Some stud-
ies demonstrated that p53 mutations play a major role in
pathogenesis of some GCCs and most of these mutations
are G:C to A:T transitions [16]. However, other studies
failed to demonstrate such alterations [8]. Allelic loss of
chromosomes 11q, 16q, and 18q is frequent in GCC and
ileal carcinoids and maybe has a role in tumorigenesis [8].
There were also three reported cases of GCC of the appen-
dix with concomitant appendiceal epithelial neoplasm.
Therefore it is assumed that their maybe a common etio-
logic factor for both GCC and epithelial neoplasm in
these cases with two components and this may be attrib-
uted to a divergent differentiation from a single stem cell
[12]. If this tumor were a true member of the carcinoid
family, then its co-existence with mucinous cysadenoma
in two reported rare cases would support the unitary stem
cell hypothesis of its origin. If this tumor is a carcinoma of
crypt cell origin rather than a carcinoid, then combination
with cystadenocarcinoma is an example of adenoma-car-
cinoma sequence that is extremely rare [29].
In conclusion, based on the review of all published papers
for nearly 600 diagnosed patients, the mean age for diag-
nosing GCC was 58.89 years with equal representation in
both genders with male to female ratio of 1:0.84. GCC of
the appendix occurs later in life in comparison to conven-
tional carcinoid. The etiopathogenic factor that most
authors agree is the occurrence of p53 mutations and this
is confirmed in most of the reported analyzed cases.
Histopathological aspects
Although GCC was previously considered a variant of car-
cinoid tumor, current evidence suggests that GCC is a dis-
tinct tumor with a histogenesis different from that of
typical carcinoid [8]. Appendiceal neoplasms that exhibit
aggressive behavior contain the typical nests of goblet
cells that are the essential elements for inclusion in the
category of GCC [23]. As immunohistochemical studies
have shown that GCC cells contain lysozyme, secretory
component (SC) and immunoglobulin A, it suggests that
these tumors are derived from cells similar to the lys-
ozyme-producing cells of the small intestinal crypts [27].
The GCC cells are rather larger than normal goblet cells
[10] and arise from a pluripotent cell (stem cell) as intes-
tinal APUD cell with endodermal origin with divergent
neuroendocrine and mucinous differentiation [3].
GCCs represent a composite biphasic neoplasm of two
morphologically differentiated cells, each with a common
endodermal embryogenic origin [2]. In early reports, the
GCCs were subdivided into two types: the goblet cell type
and the tubular type [23]. Goblet cell type is more com-
mon than tubular type [30]. Goblet cell type is composed
of smooth-bordered nests, usually 4 or more cells. The
tubular type is composed of small, discrete acini or
tubules lined by a single layer of cuboidal or columnar
cells. Both types possess the essential criteria for classifica-
tion as GCC [23]. The tubular type is more closely related
than goblet cell type to the usual appendiceal carcinoid in
both histological and prognostic characteristics and is
probably an evolutionary stage in the development of the
goblet cell type [23]. These cells are located below the
crypts of Lieberkühn and usually do not involve the
mucosa [3]. Cells are usually uniform with pattern of infil-
tration being nests, rosettes, or clumps without a distinct
lumen [2]. As the cells are distended with mucin, they
have crescentric nuclei arranged around the periphery of
the clumps, resembling goblet cells or signet-ring cells [2].
A few cells are multinucleated [23]. A high cellular prolif-
eration rate with dysregulation of the cell cycle and mini-
mal cytologic atypia is reported in most studies
[15,16,29,19]. Some studies do mention that the mitotic
rate is low [10,23].
The two types of granules (neuroendocrine and muci-
nous) that normally exist in GCC cells are not mixed with
one another in the same cell and are completely separate
[31,21] though in one type, the granules are membrane-
bound and sometimes fused (confluent) with adjacent
granules, constituting a loose reticular matrix [32]. Elec-
tron microscopy shows pleomorphic granules including
mucinous vacuoles of varying sizes and membrane-
bound neuroendocrine molecules [15,19]. Because of
copious production of mucin, which is predominantly
acid in type, the cells are strongly positive for mucicar-
mine, perodic acid-Schiff diastase, and alician blue
[15,22]. This mucin is a nonsulfated acid mucopolysacca-
ride and resistant to sialidase digestion [23]. The degree of
mucin production ranges from cells distended by coales-
cent mucin granules to cells with variable numbers of
smaller, dark granules [33].
Because GCC is considered to be derived from crypt cells,
there are other immunohistochemical techniques for their
diagnosis including Cytokeratin 20 (CK20), CK7 (with
the positivity of CK20 more than CK7), neuron-specific
enolase (NSE), chromogranin A, serotonin, lysozyme,
PGP 9.5, IgA and vimentin [7,14,24,27,33,34]. In general,
because of some neuroendocrine granules in the cyto-
plasm, the cells are reactive for NSE, chromogranin A,
Synaptophysin, Gerimelius stain, Fontana-Masson stain,
serotonin, substance P, peptide YY, glucagon alpha-chain
and S-100 protein [26,35]. All GCCs display extensive SC
(secretory component) reactivity [35]. It is important to
mention that synthesis of SC and transport of IgA are notPage 3 of 11
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IgA is from circulating dimeric IgA synthesized by lamina
propria plasma cells [36]. In one study, some tumors
showed weakly positive staining with antiserum to soma-
tostatin [27]. The presence of transitional or mixed endo/
exocrine cells can be proved only in semi thin sections
stained with a combination of the immunocytochemical
reaction for 5-HT and alician-blue [35]. It is also impor-
tant to mention that the reaction for NSE is somewhat
weaker in GCC than in typical carcinoids [35]. Some eosi-
nophilic (and phloxinophilic) granules, similar in size to
basal granules of crypt base cells, i.e., Kulchitsky cells, are
present in basal aspects of some cells [19].
Carcinoembryonic antigen (CEA) is one of the markers
that are diffusely positive on the plasma membrane of
tumor cells in GCC [7]. Höfler et al mentioned that SC-,
lyzozyme- and CEA-reactivity was strictly limited to the
exocrine tumor areas and was not found in endocrine cells
of the normal mucosa [35]. In one case with bilateral
ovarian metastasis, tumor cells were strongly positive for
CEA and CA19-9 [37]. Tumor cells of GCC of the appen-
dix show a preserved expression of beta-catenin and a
reduced expression of E-cadherin, compared to the
expression of these proteins in normal mucosa [7]. Most
cells are positive for synaptophysin [15] and anti p53 anti-
body [38]. Sometimes expression of cell proliferation
markers p53, cyclin D1 and p21 are increased while others
such as p16 is down regulated. [15].
The characteristics of GCCs that somewhat simulate ordi-
nary carcinoids are: 1) intramural position; 2) continuity
with basiglandular cells of the mucous membrane; and 3)
generally well-differentiated nature as well as the presence
of goblet cells, argentaffin or argyrophil cells and Paneth
cells in varying proportions [2]. Normally goblet cells
develop independently of Paneth cells but in special cir-
cumstances, Paneth cells might represent a reserve from
which goblet cells could develop [2]. Paneth cells can be
seen in between one third and one half of cases [33].
Paneth cell differentiation is predominant in tumors that
metastasize to the ovaries [16] and both argyrophil posi-
tive cells and Paneth cells can be seen in lymph nodes and
small bowel metastases [33] but only one study men-
tioned that Paneth cells were not found in the metastatic
deposits [23]. In addition, Paneth cells are located at the
periphery of cell nests [31]. Paneth cells are not the major
cells in gastrointestinal mucin-producing adenocarci-
noma but they are prominent in GCC of the appendix
[18]. One study mentioned that the presence of Paneth
cells, like APUD cells can be as part of the neoplastic proc-
ess or because of the migration [36]. Argentaffin cells are
one of the cell types in the GCC cellular mass that in addi-
tion to goblet cells proliferate during tumor growth and
both cell types are invasive [19]. Argyrophil cells are
found in nearly 88% of GCCs and argentaffin cells in
nearly 50% of GCCs [23]. The demonstration of argen-
taffin or argyrophil cells in a high percentage supports the
classification of GCC within the spectrum of carcinoids.
However, the mere presence of these cells in a tumor is not
pathognomonic for carcinoid. Argentaffin and argyrophil
cells are also seen in gastric and intestinal adenocarci-
noma and cystadenocarcinoma of the appendix, although
these cells are not as numerous as GCCs [23]. The Ham-
perl-Masson and diazo reactions for argentaffin granules
are positive predominantly in supranuclear position in
the nonvacuolated cells [21]. In addition, the argentaffin
cells also react positively to the Sevier-Munger argyrophil
stain [20]. The Churukian-Schenk and Grimelius staining
have been used for argyrophil granules too [39,5]. In gen-
eral, approximately three-fourths of the neoplastic cell
nests have sharply defined cytoplasmic areas that contain
highly electron-dense, pleomorphic enterochromaffin
granules (EG]. Enterochromaffin cells are situated basally
in the cell nest and have processes that extend either cir-
cumferentially or, less commonly, a short distance toward
the center of the cell nest. Because of the processes, the
number of these cells per cell nest may be overestimated
when viewed by light microscopy and some nests do not
contain enterochromaffin cells [31].
In summary, GCCs are derived from undifferentiated
stem cells and are different from typical carcinoids that
originate from endocrine cells in the mucosal stroma [35]
and the degree of integration of the goblet cells versus
APUD cells exists across a spectrum varying from pure
GCC to pure carcinoid tumor [32]. GCC cells have two
type of granules which are not mixed and are mainly acid
mucinous and can be recognized by different histochemi-
cal staining.
When microscopically evaluated, atypical cells show a
prominent submucosal growth pattern with diffuse infil-
tration from the submucosal layer to the subserosal layer
forming a microlumen structure. The growth pattern of
atypical cells is within the lamina propria and extends
through the muscularis propria into the subsequent
serosa without destroying the appendiceal structure [26].
Generally, GCC affects the base of the glands and infil-
trates the lamina propria and other layers [18]. In addi-
tion, in electron microscopy, there are equal number of
elongated cells containing many mitochondria and elec-
tron dense granules compressed between goblet cells. The
cell membrane of both goblet cells and elongated cells
shows complex interlocking of villous processes 90–100
nm in width [19]. In general, elongated cell nests are ori-
ented parallel to the muscle that they invade and some
branching can occasionally being observed. Many of these
cells are invested by variable layers of fibroblasts [19]. In
the mucosa, single endocrine cells can be observed incor-Page 4 of 11
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located at the periphery of tumor cell clusters, making
long cell processes [35]. Höfler et al explained features of
GCC as 1) isomorphous tumor structure, 2) the presence
of adenoid tumor cell groups in the intestinal wall, 3)
intact mucosa overlying the tumor, and 4) the presence of
endocrine cells [35].
Macroscopically, in most cases, there is no well-defined
mass. There maybe areas of indurations in the wall of the
appendix or stenosis of the lumen with diffuse fibrous
thickening of the appendix, which draw attention to the
possibility of tumor [10,40]. The depth of bowel wall
invasion is defined as follows: T1, tumor invading the
submucosa; T2, tumor invading the muscularis propria;
T3, tumor invading through the muscularis propria into
the subserosa; and T4, tumor perforating the visceral per-
itoneum or directly invading other organs or structures
[41]. The hallmark of GCC is the presence of individual
glands separated by smooth muscle or stroma and the lin-
ing cells contain intracytoplasmic mucin [28]. This tumor
is characterized by its tendency to arise within the lower
lamina propria and to infiltrate extensively through the
appendiceal wall without much tissue destruction [40].
Architecturally, GCC arises from the base of the glands
and spares the luminal mucosa. Unless perforation has
occurred, the outer muscular coats of the appendix are rel-
atively well preserved [5].
Regarding the anatomical location of the tumor, one
study mentioned that the tumor was present in 70% in the
distal segment of the appendix [42]. Regarding peri-
appendiceal involvement another study mentioned that
more than 50% serosa or mesoappendix was involved,
and in more than 60% the lymph nodes were not
involved [1]. Generally, diffuse infiltration into the peri-
appendiceal fat and perineural invasion is seen in most
cases [15]. The tumor cells are present in the muscle layers
and serosa of the appendix, in deeper layers of the appen-
dix, the tumors are more distended, with mucin causing a
ballooning effect and sometimes there are pools of extra-
cellular mucin in the muscular coat [10]. The tumor with
the most differentiated histological pattern is closest to
the lumen in all cases [10]. In some cases the only gross
feature is a localized yellow to grayish-white, soft or gelat-
inous appendiceal thickening [23]. The growth of this
tumor may be retarded by fibrosis and muscle spasm that
impairs the blood supply with some degeneration of
tumor islands [19]. Exclusive of tumors that metastasize,
the lesions for the most parts are uniform in size and
shape [23].
The majority of the metastasizing GCCs extend to the
serosa of the appendix though serosal involvement is not
necessarily an ominous finding [23]. Metastases usually
do not occur from any GCC's that does not extend beyond
the muscularis propria [23]. In some cases where metasta-
sis occurs, immunoreactivity for serotonin is seen only in
the primary tumor, but not in the metastasis, and there-
fore it is hypothesized that that the mucinous component
might have a selective ability to metastasize [43].
Review of all diagnosed patients has shown that the mes-
oappendix was involved in 21.64% of cases and
perineural involvement as the second most common
tumoral extension was seen in 2.06% of all patients.
Clinical manifestations of GCC
Clinical diagnosis of GCC is seldom made preoperatively.
Most of the patients present with signs and symptoms of
an acute appendicitis due to luminal obstruction [2,6].
The tumor cells proliferate sparsely and do not form nod-
ules. The appendiceal wall thickens diffusely with fibrous
proliferation, leading to contraction of the appendiceal
lumen, which is the cause of the appendicitis [26]. Other
manifestations include asymptomatic patients, intussus-
ception, a palpable mass, gastrointestinal bleeding,
increasing abdominal girth, chronic intermittent lower
abdominal pain, and secondary genitourinary complica-
tions [6,45]. The duration of symptoms in symptomatic
patients is in the range of 12 hours to 90 days [2]. In a
number of patients the tumor is identified incidentally
during an operation performed for some unrelated enti-
ties [2]. In women, they may also present as Krukenberg
tumors to the ovaries [46].
In those patients where the tumor metastasizes to the ova-
ries, half of them primarily presented as an ovarian mass
[47]. Some rare instances of clinical presentations include
mesenteric adenitis, intestinal obstruction (caused by
tumor infiltration of the terminal ileum) and anemia
(caused by extensive tumor infiltration of the ceacum with
mucosal ulceration) [27]. Höfler et al reported one GCC
with mucosal ulceration [35]. Although serotonin can be
detected immunohistochemically in these tumors, carci-
noid syndrome at any stage is rare [27]. Carcinoid syn-
drome or Cushing's-like syndrome, resulting from the
systemic effect of peptide secretion, indicates liver metas-
tasis [48]. Sometimes mucocele may be seen as a parallel
pathological finding around the involved GCC of appen-
dix [17]. A very rare complication of GCC of the appendix
is appendico-vesical fistula. In this report, the patient clin-
ically presented with urological symptoms. After laparot-
omy the abscess and granulation tissue involving the
appendix and bladder wall was detected and GCC was
confirmed by histopathological examination [22].
Review of the literature has shown that the most common
clinical presentations for GCC of the appendix in order of
frequency are as follows: acute appendicitis 22.5%,Page 5 of 11
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5.15% and abdominal mass in 3.09%.
Diagnosis of GCC
GCC is included under the general heading of mixed
(composite) glandular-endocrine-cell carcinomas [49].
The diagnosis is almost always made postoperatively [3].
GCCs often present clinically as a diffusely inflamed
appendix, with the diagnosis made by histological exami-
nation after surgery [15]. GCCs do not form discrete
tumors and are not suspected during operation or at gross
examination of the appendix. So, the surgical resection
margins should be examined microscopically in all
appendectomy specimens, especially in older patients, in
whom these tumors most often occur [28].
GCC should be sharply distinguished from ordinary carci-
noid tumors of the appendix, since they could behave bio-
logically like carcinoma [2]. The mode of growth with
concentration of the tumor elements within the basal part
of the mucosal lamina propria, the pattern of invasion,
growing diffusely through the layers of the wall without
causing necrosis or much tissue destruction are more
compatible with a carcinoid than with an adenocarci-
noma [30]. GCCs can be easily diagnosed when they are
of pure type [28]. The distinction between GCC and con-
ventional carcinoid is based on a quantitative estimation
of mucin production, since many carcinoids contain a lit-
tle mucin [40]. In addition, in contrast to conventional
carcinoids, GCCs contain few APUD cells and show posi-
tive staining of tumor cells for lysozyme, SC, and IgA [36].
For discriminating carcinoids and GCCs of the appendix
from other gastrointestinal carcinomas, the predomi-
nance of signet-ring cells is found in sites often involved
by metastatic signet-ring cell carcinomas of the gastroin-
testinal tract, whereas predominance of the carcinoid-cell
type is found in sites most often involved by metastasis of
conventional carcinoid tumors of appendix and GCC
[43].
The resemblance of some areas in GCCs to Brunner's
glands has been noted. However, the mucin in the latter is
essentially neutral, whereas it is predominantly acid in
GCC of the appendix [10]. In addition, in the face of
excessive mucus production and an infiltrative pattern,
differentiation from a mucinous adenocarcinoma
remains a real challenge [17]. Histological transformation
to ordinary adenocarcinoma has been observed occasion-
ally in metastatic lesions of GCC, but most adenocarcino-
matous lesions reported so far were still accompanied by
varied numbers of argyrophilic tumor cells [37]. So the
number of argyrophilic or argentaffin cells, as a tumor
component is allegedly an indicator of the malignant
potential in GCC's of the appendix with nonmetastasizing
tumors commonly containing numerous neuroendo-
crine-type cells [37]. GCC of the appendix can be regarded
as a peculiar type of adenocarcinoma, particularly when
the number of neuroendocrine-type cells is limited [37].
In histological aspects for differential diagnosis, muci-
nous carcinomas differ from GCCs by the presence of
glandular fusion and lack of glandular lumina within the
mucin lakes [28]. Distinction between mucinous cystade-
nocarcinoma of appendix and GCC should also be con-
sidered. In the former, the mucosa lining the lumen is
itself neoplastic, unlike GCC where the overlying epithe-
lium appears normal with neoplastic transformation
occurring from the deeper layers of the mucosa [17].
In most reports of metastasizing GCCs, the patients
present with spread beyond the appendix at initial diag-
nosis [28]. In several reported cases, the ovarian masses
were detected before the appendiceal tumor was recog-
nized. In this clinical setting, the danger of misdiagnosing
either a primary ovarian neoplasm or a metastasis from
another site is high [5]. When mucin producing solid
ovarian tumor is found without an extra-ovarian primary
tumor during operation for another reason, then a diag-
nostic appendectomy should also be performed concom-
itantly [48]. When cystic mucinous tumors of the ovary
showing bilateral involvement and/or stromal invasion
by signet ring-type cells are encountered, the possibility of
metastasis from an appendiceal GCC should be consid-
ered, irrespective of the presence or absence of argy-
rophilic tumor cells [37]. In-labeled octreotide
scintigraphy is useful for diagnosis and staging of metas-
tasis.
Paraclinical aspects of GCC
The white blood cell count is generally elevated with pre-
dominantly polymorphonuclear leukocytes and a "shift
to the left," especially in patients presenting with acute
symptoms [2,20]. However, it can be within normal range
in some patients [2]. Generally, c-reactive protein is
slightly elevated [7]. In one reported case with metastasis
to ovaries, serum level of CEA was elevated [37] and in
another report, plasma serotonin level was elevated pre-
operatively but these do not occur frequently [5]. Urinary
5-hydroxyindoleacetic acid (5-HIAA) level is estimated to
be mostly within normal limits [27]. In cases with liver
metastasis, liver enzymes and serum bilirubin will be ele-
vated [43]. One of the rare complications of GCC of the
appendix and all mucinous tumors of the appendix and or
ovary is the occurrence of pseudomyxoma peritonei. This
is a neoplastic disease of MUC2-expressing goblet cells,
which collectively overexpress MUC2 because of their
increase in number. Goblet cells of the appendix express
both MUC2 and MUC5AC mucins but primary ovarian
mucinous tumors only express MUC5AC. So measuring
MUC2 is a specific marker for diagnosis of appendiceal
induced pseudomyxoma peritonei [49,51].Page 6 of 11
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with fluid levels when obstruction occurs [45]. Cross-sec-
tional imaging with CT is the technique of choice for any
suspected appendiceal mass to rule out a tumor. In this
technique the findings for GCC reflects the infiltrative
nature of the tumor, with mild but diffuse mural thicken-
ing [6].
Surgical therapy of GCC
The site of the tumor within the appendix is not important
for the choice of treatment [51]. In general, therapy is sur-
gical. Even though GCC has a more aggressive phenotype
than benign carcinoid tumors, the prognosis is generally
good in a patient who is treated by simple appendectomy.
Appendectomy remains the treatment of choice in the
majority of patients. In some patients however a more
radical procedure is indicated especially in the presence of
diffuse appendiceal involvement [38,2,3]. Recently Var-
isco et al emphasized that in patients with no concomitant
caecal involvement and low-grade tumor's histology; a
simple appendectomy is enough [52].
Some studies recommend that because GCCs are among
the semi high-grade malignant carcinoids with unpredict-
able behavior, in addition to simple appendectomy a
right hemicolectomy should also be performed [45,42].
The general consensus remains that a right hemicolec-
tomy should be performed when one or more of the fol-
lowing criteria are noted: 1), cellular undifferentiation; 2),
increased mitotic activity; 3), involvement of the base of
the appendix with caecal wall infiltration; 4), lymph node
metastasis; and 5), tumor size greater than 2 cm. Invasion
only into the mesoappendix or histological findings of
intralymphatic or perineural invasion does not necessar-
ily, by itself, require a more radical procedure [2]. How-
ever, if it cannot be confirmed that the base of the
appendix is tumor-free, a right hemicolectomy is indi-
cated due to the frequency of regional nodal metastases
[27]. One study explained the indication of right hemi-
colectomy based on: incomplete excision of the tumor,
foci of dedifferentiation and two or more mitotic figures
per ten high power fields [25].
In addition to right hemicolectomy, some authors also
advocate bilateral oophorectomy in female patients
because of the possibility of ovarian metastasis [46,48].
Conversely, due to the tendency of GCCs affinity of
spread to the ovaries, it is recommended that an appen-
dectomy be routinely performed in patients with Kruken-
berg's tumor of the ovary where no gross obvious primary
neoplasm can be found [53]. So, if an intraoperative his-
tological evaluation reveals metastatic ovarian tumor, and
at the same time, an obvious primary lesion is apparently
absent, thorough exploration of the appendix is manda-
tory and routine appendectomy is recommended even if
the appendix appears macroscopically normal [46]. In
disseminated disease of the appendix in the abdomen,
radical surgery is not recommended because it is doubtful
that the course of the disease will be altered [48]. Thus,
until better prognostic markers can be identified, an elec-
tive right hemicolectomy offers the best chance of control-
ling the disease and preventing recurrence in such patients
[54,42]. As the route of metastatic spread of GCC's is
through lymphatic and venous drainage, one should
check the areas on the anterior surface of the third portion
of the duodenum and above the origin of the ileocolic
artery for metastatic deposits [55].
Even though the GCC of the appendix is not a complete
high-grade malignant tumor, it can recur and metastasize
so complete removal is imperative [10]. It is emphasized
that recognition of this disease during the appendectomy
from clues such as an abnormally thickened appendiceal
wall, or the retention of mucinous material in the lumen
should be encouraged [7].
Review of all reported GCCs showed that simple appen-
dectomy was performed in nearly 24.57% of cases espe-
cially in the early reports. The most common surgical
treatment of choice was appendectomy with right hemi-
colectomy (RHC) especially in the recent reports (34.7%).
Oophorectomy was also performed in nearly 11.39% of
female patients. In conclusion, because of the moderately
aggressive behavior of the tumor, it is recommended that
in all patients in addition to appendectomy a right hemi-
colectomy is also performed. As the mean age of the
patients is over 50 and ovaries are the most common sites
of metastasis, and bilateral involvement of the ovaries is
the commonest metastatic behavior, bilateral salpingo-
oophorectomy with total abdominal hysterectomy (TAH-
BSO) is also advocated in selected female patients. Addi-
tional file: 1 summarizes the management of all diag-
nosed GCCs based on chronological reporting.
Adjuvant therapy of GCC
Peritoneal carcinomatosis from GCC origin is as invasive
as peritoneal surface malignancy from colorectal adeno-
carcinoma. Patients in whom complete or near-complete
surgical removal is possible should be considered for
cytoreduction in combination with intraperitoneal chem-
otherapy [56].
As GCC's have this capacity to seed diffusely into the peri-
toneal cavity, innovative chemotherapy regimens similar
to gastric cancer chemotherapy is advocated though in
one study chemotherapy was administered without suc-
cessful response [3]. One study of GCC with subserosal
involvement advocated postoperative chemotherapy with
5-FU, Leucovorin, and CPT-11 [8]. Some authors mention
that even small tumors early in the course of the diseasePage 7 of 11
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results in release of tumor cells into the free peritoneal
cavity and this almost occurs before lymph node metasta-
sis and therefore advocate the routine usage of interaperi-
toneal chemotherapy. There is no added benefit using
either combination of mitomycin C plus 5-FU versus cis-
platin plus Adriamycin [57]. There is also one report of a
patient with GCC of the appendix and bilateral ovarian
metastasis receiving X-ray radiation therapy as an adju-
vant and after 8 months follow-up, no recurrence was
detected [55]. Wojcik et al reported the first case of GCC
on peritoneal fluid cytology in a woman with a prior his-
tory of carcinoid tumor of the appendix and the patient
underwent 11 courses of Adriamycin and alpha-interferon
with unknown documented follow-up [49]. A regimen of
5-FU and streptozocin was recommended in a case with
appendiceal GCC and bilateral Krukenberg's of the ova-
ries and the patient was alive after 7 months follow-up
[53]. There is also another report of GCC with Kruken-
berg's tumor, which advocated that cisplatin-based chem-
otherapy has some therapeutic benefits [46]. In general,
Krukenberg's tumors subgroup due to appendiceal GCC
has a survival advantage in patients receiving surgery and
adjuvant therapy compared to surgery alone [34]. In one
reported case with bilateral ovarian metastases patient
was treated with carboplatin, cyclophosphamide and pir-
arubicin and followed by 9 months outpatient tegafur
uracil (UTF) [37]. A recent study mentioned that a folfox
chemotherapy that includes oxaliplatin combined with 5-
FU and leucovorin is helpful in complete and persistent
remission of a GCC case with metastasis to ovaries, peri-
toneal cavity and lymph nodes [58]. A summary of all
reported GCCs and their management including chemo-
therapy is shown in Additional file: 1.
Even though it was not prescribed routinely, most proto-
cols include 5-FU. As peritoneal seeding can occur before
lymph node metastasis and there is proven advantage of
chemotherapy in metastatic patients, 5-FU is therefore
highly recommended in all GCC patients. Radiotherapy
was only ordered in 4 cases without any specific conse-
quence.
Follow-up of patients with GCC
Metastasis occurs in nearly 20% of the cases [16]. In gen-
eral, metastatic ability is calculated in a range from 0 to 50
% [40]. The most common route of metastasis is through
lymphatic vessels, trans-celomic and intraperitoneal inva-
sion [27,33]. However, hematogenous metastasis to the
liver or other distant organs is rarely mentioned [33].
Metastasis beyond the appendix is more frequent in older
patients [27]. Metastasis from GCCs of the appendix has
been described to the ovaries, pelvis, abdominal cavity,
rib, vertebra, and lymph nodes [2,52]. The ovary is the
most common target site of metastasis of GCC and meta-
static lesions sometimes show a histological picture of
mucin-producing adenocarcinoma [37]. In general, when
metastatic spread occurs, it shows a predilection for the
peritoneum and ovaries, with peritoneal carcinoidosis
[43]. GCC's have a propensity to metastasize to the ova-
ries indistinguishable from the typical Krukenberg's
tumor [46]. Primary ovarian carcinoids are invariably uni-
lateral, whereas metastatic carcinoids to the ovaries are
almost always bilateral or unilateral with extraovarian
involvement [34]. In female patients with metastatic
GCCs, ovarian involvement is seen in almost 90% of cases
and is the source for further tumor dissemination [16].
Liver metastasis with abnormal liver function tests and
hepatomegaly was also seen occasionally [27]. In meta-
static deposits to organs including ovaries, fallopian
tubes, uterus, and colon the histology is different and
mostly composed by signet-ring cells without typical car-
cinoid cells but the metastases to liver and lymph nodes
show a pattern of typical midgut carcinoids with signet-
ring cells centrally and carcinoid cell type peripherally
[43]. Also in rare cases only the mucinous component
may spread and metastasize [39].
In-labeled octreotide scintigraphy is the most sensitive
imaging modality in the diagnosis and staging of meta-
static disease. Plasma chromogranin A is the most impor-
tant blood marker available with levels being raised in
80–100 percent of patients with neuroendocrine tumors
including GCC. Chromogranin A levels correspond to
tumor load and levels above 5000 µg/l predict a poor out-
come. Therefore, all patients with GCCs warrant investiga-
tion with plasma chromogranin A concentration, 24-h
urinary levels of 5-HIAA, CT and In-labeled octreotide
scintigraphy [45]. Where appendectomy has been done as
the only treatment, prolonged follow-up is recommended
and may involve laparoscopy in view of the risk of trans-
celomic spread [27]. One study mentioned that pancreatic
polypeptide might be useful as a tumor marker for follow-
up purposes [27].
Review of the literature has shown that 11.2% of the
patients were diagnosed with concomitant distant metas-
tasis with ovaries being the most common site (3.60%)
followed by abdominal carcinomatosis (1.03%). In addi-
tion, local lymph node involvement was seen in 8.7% of
patients at the time of diagnosis. After surgical treatment,
metastasis occurred in 4.1% of patients most commonly
with abdominal carcinomatosis in 1.37% followed by
ovaries in 0.85%. In conclusion, when GCC is suspected,
both the ovaries and the peritoneum should be examined
both during surgical extirpation and during follow up.
Prognosis of GCC
The prognosis of these tumors is estimated to be some-
where between carcinoids and well-differentiated adeno-Page 8 of 11
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favorable except in those patients who present with the
more virulent form, delayed local recurrence, lung metas-
tases or dual neoplasia e.g., GCC/epithelial neoplasia. In
dual neoplasia prognosis depends on the stage and grade
of the other component [3]. The association of GCC of the
appendix with other cancers also clearly worsens the prog-
nosis of the patient [2]. The associated carcinomas are
most commonly carcinoma of the urinary bladder, pros-
tate, ovaries, stomach and breast [2]. Other study however
suggested that the prognosis of dual appendiceal GCC/
epithelial neoplasia would be no worse than for either of
the components alone [12]. There are also two reported
rare cases of GCC and mucinous cystadenoma of the
appendix with no information on their prognosis and
outcome [29]. Involvement of the base of the appendix
with only limited caecal wall involvement may still carry
a favorable prognosis. Extension of the tumor beyond the
appendix to the ovaries or the abdominal cavity, however,
greatly worsens the prognosis [2]. In general, when tumor
metastasis to the ovary is present, the prognosis is poor
with a mean survival of 7 to 9 months [47]. Widespread
intraabdominal dissemination can be fatal even in a short
time [48].
Histological features such as nuclear pleomorphism and
mitotic activity show no significant correlation with stag-
ing or prognosis [27]. On the other hand, some authors
say the vast majority of GCCs that metastasize have spread
beyond the serosa, suggesting that stage is another impor-
tant prognostic factor [16]. Tumor characteristics that pre-
dict aggressive behavior include size, histological subtype
and mesoappendiceal involvement [45]. Discussion
regarding tumor size is controversial. Some studies say
that size is not a good indicator for prognosis because
these lesions do not always form discrete masses [3].
Other studies say the tumor size is only related to the met-
astatic potential and tumors larger than 2 cm are associ-
ated with a poorer prognosis. However, even smaller
tumors do occasionally metastasize [48]. Angioinvasion
should be regarded as a feature of more malignant behav-
ior. In general, serosal involvement and mesoappendiceal
extension are more predictive of outcome than lymph
node status [45]. One study reported that those GCC
tumors that show positive staining for pancreatic
polypeptide behave in an aggressive fashion [27].
As a rule, survival for GCC of appendix is not significantly
worse than that for patients with malignant carcinoid
when adjusted for age and extent of disease at presenta-
tion, and is similar to survival after treatment of a low-risk
adenocarcinoma [45]. One report referred to increasing
age and evidence of tumor spread as poor prognostic fac-
tors [27]. In addition, reduced E-cadherin staining and
overexpression of p21 need further assessment as future
prognostic follow-up markers [59]. Another study men-
tioned that 20% of appendiceal GCCs that metastasize
result in death [16]. The reported 5-year survival of GCC
is between 60% and 84% [61,15,12,60,8,53] and 16% of
all cases have recurrence of the disease [54].
Generally, the behavior of GCC is unpredictable and can-
not be anticipated from the tumor's diameter, as in the
case with carcinoid tumors [25]. Average survival time is
4.6 years with a range of 6 months to 20 years [25].
Conclusion
GCC of the appendix is a rare neoplasm that has varied
clinical presentations ranging from an asymptomatic
patient that is recognized during investigations for
another problem, to acute appendicitis, the most com-
mon presentation, and toward the other end of the spec-
trum the metastatic presentation like Krukenberg's tumor
or widespread peritoneal metastatic disease. So with this
wide range of presentation, GCC should be always consid-
ered as a differential diagnosis in patients with "suspected
appendicitis" with or without a mass leading to abdomi-
nal surgery. After the tumor is histologically confirmed,
some factors need to be evaluated histologically as predic-
tive factors for the biological behavior, e.g., the increased
number of Paneth cells, increased mucin secretion and
positivity for pancreatic polypeptide show a more aggres-
sive and metastatic behavior and such cases should be
considered for long-term follow-up. As nearly 20% show
metastatic behavior and high possibility of intraperito-
neal seeding before lymph node involvement, appendec-
tomy with completion right hemicolectomy is
recommended for all patients with caecal involvement
and or high-grade tumors. Moreover, as the most com-
mon sites of metastasis are ovaries, in female patients,
regardless of age and involvement, bilateral salpingo-
oophorectomy is also recommended. In the presence of
metastasis, combination chemotherapy regimes include
5-FU and leucovorin. It should be kept in mind that
despite different terminology the biological difference
between adenocarcinoid and carcinoma is not significant.
Peritoneal carcinomatosis from adenocarcinoid of appen-
diceal origin is as invasive as peritoneal surface malig-
nancy from colorectal adenocarcinoma. Patients in whom
complete or near-complete surgical removal is possible
should be considered for cytoreduction in combination
with intraperitoneal chemotherapy. Based on the tumor
histological predictors, long-term follow-up should be
routinely advocated in all cases for possible metastasis. In
this context, In-labeled octreotide scintigraphy is recom-
mended for diagnosis and long-term follow-up of this
neoplasm.Page 9 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2005, 3:36 http://www.wjso.com/content/3/1/36Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PSP: Is the first and the corresponding author, Concep-
tion and design, Literature review with references, Draft-
ing the article and revising, provided statistical analysis of
the reviewed data, preparation of table.
RK: helping in the preparation and drafting the manu-




the authors would like to thank Prof. Wolfgang Kuschinsky, the director of 
the department of physiology and pathophysiology, University of Heidel-
berg, Germany. This study was started and finished at his department.
References
1. McCusker ME, Cote TR, Clegg LX, Sobin LH: Primary malignant
neoplasms of the appendix: a population-based study from
the surveillance, epidemiology and end-results program,
1973–1998.  Cancer 2002, 94:3307-3312.
2. Berardi RS, Lee SS, Chen HP: Goblet cell carcinoids of the
appendix.  Surg Gynecol Obstet 1988, 167:81-86.
3. Butler JA, Houshiar A, Lin F, Wilson SE: Goblet cell carcinoid of
the appendix.  Am J Surg 1994, 168:685-687.
4. Ratzenhofer M, Aubock L: The amphicrine (endo-exocrine) cells
in the human gut, with a short reference to amphicrine neo-
plasias.  Acta Morphol Acad Sci Hung 1980, 28:37-58.
5. Edmonds P, Merino MJ, LiVolsi VA, Duray PH: Adenocarcinoid
(mucinous carcinoid) of the appendix.  Gastroenterology 1984,
86:302-309.
6. Pickhardt PJ, Levy AD, Rohrmann  CA Jr, Kende AI: Primary neo-
plasms of the appendix: radiologic spectrum of disease with
pathologic correlation.  Radiographics 2003, 23:645-662.
7. Kuroda N, Mizushima S, Guo L, Jin Y, Tao L, Miyazaki E, Toi M,
Naruse K, Hiroi M, Enzan H: Goblet cell carcinoid of the appen-
dix: Investigation of the expression of beta-catenin and E-
cadherin.  Pathol Int 2001, 51:283-287.
8. Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR, Rashid A:
Genetic alterations in goblet cell carcinoids of the vermi-
form appendix and comparison with gastrointestinal carci-
noid tumors.  Mod Pathol 2003, 16:1189-1198.
9. Lancaster KJ, Liang CY, Myers JC, McCabe KM: Goblet cell carci-
noid arising in a mature teratoma of the mediastinum.  Am J
Surg Pathol 1997, 21:109-113.
10. Subbuswamy SG, Gibbs NM, Ross CF, Morson BC: Goblet cell car-
cinoid of the appendix.  Cancer 1974, 34:338-344.
11. Wolff M: Crypt cell carcinoma.  Am J Surg Pathol 1982, 6:188-189.
12. Carr NJ, Remotti H, Sobin LH: Dual carcinoid/epithelial neopla-
sia of the appendix.  Histopathology 1995, 27:557-562.
13. Li CC, Hirowaka M, Qian ZR, Xu B, Sano T: Expression of E-cad-
herin, b-catenin, and Ki-67 in goblet cell carcinoids of the
appendix: an immunohistochemical study with clinical cor-
relation.  Endocr Pathol 2002, 13:47-58.
14. Zea-Iriarte WL, Ito M, Naito S, Nakayama T, Itsuno M, Fujii H, Furu-
kawa M, Makiyama K, Sekine I: Goblet cell carcinoid of the
appendix.  Intern Med 1994, 33:422-426.
15. Kanthan R, Saxena A, Kanthan SC: Goblet cell carcinoids of the
appendix: immunophenotype and ultrastructural study.  Arch
Pathol Lab Med 2001, 125:386-390.
16. Ramnani DM, Wistuba II, Behrens C, Gazdar AF, Sobin LH, Albores-
Saavedra J: K-ras and p53 mutations in the pathogenesis of
classical and goblet cell carcinoids of the appendix.  Cancer
1999, 86:14-21.
17. Chen V, Qizilbash AH: Goblet cell carcinoid tumor of the
appendix. Report of five cases and review of the literature.
Arch Pathol Lab Med 1979, 103:180-182.
18. Haqqani MT, Williams G: Mucin producing carcinoid tumors of
the vermiform appendix.  J Clin Pathol 1977, 30:473-480.
19. Warner TF, SEo IS: Goblet cell carcinoid of appendix:
ultrastructural features and histogenetic aspects.  Cancer
1979, 44:1700-1706.
20. Klein HZ: Mucinous carcinoid tumor of the vermiform appen-
dix.  Cancer 1974, 33:770-777.
21. Abt AB, Carter SL: Goblet cell carcinoid of the appendix. An
ultrastructural and histochemical study.  Arch Pathol Lab Med
1976, 100:301-306.
22. Di Paola M, Stockwell WS: Appendico-vesical fistula due to an
appendix abscess with associated goblet cell carcinoid of the
appendix.  Br J Urol 1976, 48:436.
23. Warkel RL, Cooper PH, Helwig EB: Adenocarcinoid, a mucin-
producing carcinoid tumor of the appendix: a study of 39
cases.  Cancer 1978, 42:2781-2793.
24. Kende AI, Carr NJ, Sobin LH: Expression of cytokeratins 7 and
20 in carcinomas of the gastrointestinal tract.  Histopathology
2003, 42:137-140.
25. Gallegos NC, Milroy C, Linehan IP, Boulos PB: Crypt cell carci-
noma of the appendix.  Eur J Surg Oncol 1992, 18:386-387.
26. Aizawa M, Watanabe O, Naritaka Y, Katsube T, Imamura H, Kinoshita
J, Shimakawa T, Kobayashi S, Asaka S, Haga S, Ogawa K, Aiba M, Kaji-
wara T: Adenocarcinoid of the appendix: report of two cases.
Surg Today 2003, 33:375-378.
27. Anderson NH, Somerville JE, Johnston CF, Hayes DM, Buchanan KD,
Sloan JM: Appendiceal goblet cell carcinoids: a clinico-patho-
logical and immunohistochemical study.  Histopathology 1991,
18:61-65.
28. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB: Goblet
cell carcinoids and related tumors of the vermiform appen-
dix.  Am J Clin Pathol 1990, 94:27-35.
29. AL-Talib RK, Mason CH, Theaker JM: Combined goblet cell car-
cinoid and mucinous cystadenoma of the appendix.  J Clin
Pathol 1995, 48:869-870.
30. Olsson B, Ljungberg O: Adenocarcinoid of the vermiform
appendix.  Virchows Arch A Pathol Anat Histol 1980, 386:201-210.
31. Cooper PH, Warkel RL: Ultrastructure of the goblet cell type
of adenocarcinoid of the appendix.  Cancer 1978, 42:2687-2695.
32. Rodriguez  FH Jr, Sarma DP, Lunseth JH: Goblet cell carcinoid of
the appendix.  Hum Pathol 1982, 13:286-288.
33. Watson PH, Alguacil-Garcia A: Mixed crypt cell carcinoma. A
clinicopathological study of the so-called 'goblet cell carci-
noid'.  Virchows Arch A Pathol Anat Histopathol 1987, 412:175-182.
34. Klein EA, Rosen MH: Bilateral Krukenberg tumors due to
appendiceal mucinous carcinoid.  Int J Gynecol Pathol 1996,
15:85-88.
35. Hofler H, Kloppel G, Heitz PU: Combined production of mucus,
amines and peptides by goblet-cell carcinoids of the appen-
dix and ileum.  Pathol Res Pract 1984, 178:555-561.
36. Isaacson P: Crypt cell carcinoma of the appendix (so-called
adenocarcinoid tumor).  Am J Surg Pathol 1981, 5:213-224.
37. Ikeda E, Tsutsumi Y, Yoshida H, Yanagi K: Goblet cell carcinoid of
the vermiform appendix with ovarian metastasis mimicking
mucinous cystadenocarcinoma.  Acta Pathol Jpn 1991,
41:455-460.
38. Horiuchi S, Endo T, Shimoji H, Takahashi H, Mitsuuchi M, Yawata A,
Mita H, Yoshida M, Arimura Y, Sakamoto H, Itoh F, Hinoda Y, Imai K,
Sasaki K, Sato M: Goblet cell carcinoid of the appendix endo-
Additional file 1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7819-3-36-S1.doc]Page 10 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2005, 3:36 http://www.wjso.com/content/3/1/36Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
scopically diagnosed and examined with p53 immunostain-
ing.  J Gastroenterol 1998, 33:582-587.
39. Miller RT, Sarikaya , Jenison EL: Adenocarcinoid tumor of appen-
dix presenting as unilateral Krukenberg tumor.  J Surg Oncol
1988, 37:65-71.
40. Bak M, Asschenfeldt P: Adenocarcinoid of the vermiform
appendix. A clinicopathologic study of 20 cases.  Dis Colon Rec-
tum 1988, 31:605-612.
41. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tan-
abe KK, Ott MJ: Prognosis and survival in patients with gas-
trointestinal tract carcinoid tumors.  Ann Surg 1999,
229:815-821.
42. Park K, Blessing K, Kerr K, Chetty U, Gilmour H: Goblet cell car-
cinoid of the appendix.  Gut 1990, 31:322-324.
43. Bak M, Jorgensen LJ: Adenocarcinoid of the appendix present-
ing with metastases to the liver.  Dis Colon Rectum 1987,
30:112-115.
44. Torres-melero J, Garcia-Calvo M, Blanco S, Navarro MD, Sanchez-
Pernaute A, Suarez B, Ortega L, Balibrea JL: An adenocarcinoid
tumor of the vermiform appendix.  Rev Esp Enfem Dig 1994,
86:771-773.
45. Goede AC, Caplin ME, Winslet MC: Carcinoid tumor of the
appendix.  Br J Surg 2003, 90:1317-1322.
46. Mandai M, Konishi I, Tsuruta Y, Suginami N, Kusakari T, Iwasaki T,
Fujii S: Krukenberg tumor from an occult appendiceal adeno-
carcinoid: a case report and review of the literature.  Eur J
Obstet Gynecol Reprod Biol 2001, 97:90-95.
47. Baker PM, Oliva E, Young RH, Talerman A, Scully RE: Ovarian muci-
nous carcinoids including some with a carcinomatous com-
ponent: a report of 17 cases.  Am J Surg Pathol 2001, 25:557-568.
48. Tjalma WA, Schatteman E, Goovaerts G, Verkinderen L, Van-den
Borre F, Keersmaekers G: Adenocarcinoid of the appendix pre-
senting as a disseminated ovarian carcinoma: report of a
case.  Surg Today 2000, 30:78-81.
49. Wojcik EM, Selvaggi SM: Goblet-cell carcinoid tumor in perito-
neal fluid: a case report.  Diagn Cytopathol 1991, 7:155-157.
50. O'Connell JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH:
Pseudomyxoma peritonei is a disease of MUC2-expressing
goblet cells.  Am J Pathol 2002, 161:551-564.
51. Larsen SG, Nilssen A, Helseth A, Bohler P, Giercksky KE: Invagina-
tion of the appendix with carcinoid tumor.  Eur J Surg 1999,
165:993-997.
52. Varisco B, McAlvin B, Dias J, Franga D: Adenocarcinoid of the
appendix: is right hemicolectomy necessary? A meta-analy-
sis of retrospective chart reviews.  Am Surg 2004, 70:593-599.
53. Hirschfield LS, Kahn LB, Winkler B, Bochner RZ, Gibstein AA: Ade-
nocarcinoid of the appendix presenting as bilateral Kruken-
berg's tumor of the ovaries. Immunohistochemical and
ultrastructural studies and literature review.  Arch Pathol Lab
Med 1985, 109:930-933.
54. Smith JA: Goblet cell carcinoid of the appendix.  Gut 1990,
31:840.
55. Heisterberg L, Wahlin A, Nielsen KS: Two cases of goblet cell car-
cinoid tumor of the appendix with bilateral ovarian metas-
tases.  Acta Obstet Gynecol Scand 1982, 61:153-156.
56. Mahteme H, Sugarbaker PH: Treatment of peritoneal carcino-
matosis from adenocarcinoid of appendiceal origin.  Br J Surg
2004, 91:1168-1173.
57. Sugarbaker PH: Management of peritoneal surface malig-
nancy: Appendix cancer and pseudomyxoma peritonei,
colon cancer, gastric cancer, abdominopelvic sarcoma, and
primary peritoneal malignancy, clinical results of treatment.
[http://www.surgicaloncology.com/psmreslt.htm]. Assessed on June
6, 2005
58. Grain L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul JL:
Adenocarcinoid of the appendix vermiformis: complete and
persistent remission after chemotherapy (folfox) of a meta-
static case.  Dig Dis Sci 2002, 47:2760-2762.
59. Kawahara M, Kammori M, Kanauchi H, Noguchi C, Kuramoto S,
Kaminishi M, Endo H, Takubo K: Immunohistochemical prognos-
tic indicators of gastrointestinal carcinoid tumours.  Eur J Surg
Oncol 2002, 28:140-146.
60. Ludtke-Handjery A, Pickartz H, Strietzel S: Goblet cell carcinoid of
the vermiform appendix.  Leber Magen Darm 1991, 21:226,
229-230.
61. Berardi RS, Chen H: Goblet cell carcinoid of the appendix.  Int
Surg 1989, 74:109-110.
62. Argani P, van Hoeven KH, Artymyshyn RL: Diagnosis of meta-
static appendiceal adenocarcinoid in liver by fine-needle
aspiration cytology.  Diagn Cytopathol 1995, 12:59-61.
63. Zirkin RM, Brown S, Hertz M: Adenocarcinoid of appendix pre-
senting as bilateral ovarian tumors. A case report with histo-
chemical and ultrastructural studies.  Diagn Gynecol Obstet 1980,
2:269-274.Page 11 of 11
(page number not for citation purposes)
